By a News Reporter-Staff News Editor at Gene Therapy Weekly -- New research on Therapeutics is the subject of a report. According to news reporting out of London, United Kingdom, by NewsRx editors, research stated, "Gene therapy is a powerful approach to treat disease locally. However, if the therapeutic target is intracellular, the therapeutic will be effective only in the cells where the therapeutic gene is delivered."
Our news journalists obtained a quote from the research from Queen Mary University, "We have engineered a fusion protein containing an intracellular inhibitor of the transcription factor NF-B pathway that can be effectively secreted from producing cells. This fusion protein is cleaved extracellularly by metalloproteinases allowing release of a protein transduction domain (PTD) linked to the NF-B inhibitor for translocation into neighboring cells. We show that engineered molecules can be efficiently secreted (>80%); are cleaved with matrix metalloprotease-1; inhibit NF-B driven transcription in a biological assay with a human reporter cell line; and display significant inhibition in mouse paw inflammation models when delivered by lentivirus or secreting cells. No inhibition of NF-B transcription or therapeutic effect was seen using molecules devoid of the PTD and NF-B inhibitory domains."
According to the news editors, the research concluded: "By creating a fusion protein with an endogenous secretion partner, we demonstrate a novel approach to efficiently secrete PTD-containing protein domains, overcoming previous limitations, and allowing for potent paracrine effects.Koutsokeras, A., Purkayashta, N., Rigby, A., Subang, M. C., Sclanders, M., Vessillier, S., Mullen, L., Chernajovsky, Y., Gould, D. Generation of an efficiently secreted, cell penetrating NF-B inhibitor."
For more information on this research see: Generation of an efficiently secreted, cell penetrating NF-kB inhibitor. Faseb Journal, 2014;28(1):373-381. Faseb Journal can be contacted at: Federation Amer Soc Exp Biol, 9650 Rockville Pike, Bethesda, MD 20814-3998, USA (see also Therapeutics).
Our news journalists report that additional information may be obtained by contacting A. Koutsokeras, Queen Mary University, Bone & Joint Res Unit, Barts & London Sch Med & Dental, London EC1M 6BQ, United Kingdom. Additional authors for this research include N. Purkayashta, A. Rigby, M.C. Subang, M. Sclanders, S. Vessillier, L. Mullen, Y. Chernajovsky and D. Gould.
Keywords for this news article include: Biotechnology, London, Europe, Gene Therapy, Therapeutics, United Kingdom, Bioengineering, Fusion Proteins
Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2014, NewsRx LLC